SX682-MDS-102 A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Myelodysplastic Syndrome Who Had Disease Progression or are Intolerant to Prior Therapy

NCT04245397

A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Myelodysplastic Syndrome Who Had Disease Progression or are Intolerant to Prior Therapy

Associated Conditions

Myelodysplastic Syndrome

Principal Investigator

Sponsor

Syntrix Biosystems, Inc

This research study is studying an investigational immunotherapy called SX-682 as a possible treatment for Myelodysplastic Syndrome.

This study is currently enrolling.